112 related articles for article (PubMed ID: 31609776)
1. Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer.
Hamid AA; Choudhury AD
Curr Opin Urol; 2020 Jan; 30(1):30-35. PubMed ID: 31609776
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy and gene therapy in prostate cancer treatment.
Grozescu T; Popa F
J Med Life; 2017; 10(1):54-55. PubMed ID: 28255378
[TBL] [Abstract][Full Text] [Related]
3. The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology.
Di Giacomo AM; Covre A; Giacobini G; Ibrahim R; Lyman J; Natali PG; Maio M
Cancer Immunol Immunother; 2019 Jan; 68(1):143-150. PubMed ID: 30564888
[TBL] [Abstract][Full Text] [Related]
4. Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer.
Séguier D; Adams ES; Kotamarti S; D'Anniballe V; Michael ZD; Deivasigamani S; Olivier J; Villers A; Hoimes C; Polascik TJ
Nat Rev Urol; 2024 May; 21(5):290-302. PubMed ID: 38114768
[TBL] [Abstract][Full Text] [Related]
5. Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.
Annapragada A; Sikora A; Bollard C; Conejo-Garcia J; Cruz CR; Demehri S; Demetriou M; Demirdjian L; Fong L; Horowitz M; Hutson A; Kadash-Edmondson K; Kufe D; Lipkin S; Liu S; McCarthy C; Morgan M; Morris Z; Pan Y; Pasquini M; Schoenberger S; Van Allen E; Vilar E; Xing Y; Zha W; ; Odunsi A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554617
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.
Miyahira AK; Zarif JC; Coombs CC; Flavell RR; Russo JW; Zaidi S; Zhao D; Zhao SG; Pienta KJ; Soule HR
Prostate; 2022 Feb; 82(2):169-181. PubMed ID: 34734426
[TBL] [Abstract][Full Text] [Related]
7. Major milestones in translational oncology.
Dragani TA; Castells A; Kulasingam V; Diamandis EP; Earl H; Iams WT; Lovly CM; Sedelaar JP; Schalken JA
BMC Med; 2016 Jul; 14(1):110. PubMed ID: 27469586
[TBL] [Abstract][Full Text] [Related]
8. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee.
Gastman B; Agarwal PK; Berger A; Boland G; Broderick S; Butterfield LH; Byrd D; Fecci PE; Ferris RL; Fong Y; Goff SL; Grabowski MM; Ito F; Lim M; Lotze MT; Mahdi H; Malafa M; Morris CD; Murthy P; Neves RI; Odunsi A; Pai SI; Prabhakaran S; Rosenberg SA; Saoud R; Sethuraman J; Skitzki J; Slingluff CL; Sondak VK; Sunwoo JB; Turcotte S; Yeung CC; Kaufman HL
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199512
[TBL] [Abstract][Full Text] [Related]
9. Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.
Baik CS; Rubin EH; Forde PM; Mehnert JM; Collyar D; Butler MO; Dixon EL; Chow LQM
Clin Cancer Res; 2017 Sep; 23(17):4992-5002. PubMed ID: 28864727
[TBL] [Abstract][Full Text] [Related]
10. Multiplex imaging in immuno-oncology.
Zhao C; Germain RN
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899132
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Recent advances in discovering molecular targets for cancer therapy.
Yang Z; Wang T
Front Med (Lausanne); 2024; 11():1403466. PubMed ID: 38779619
[No Abstract] [Full Text] [Related]
12. Revisiting Immunotherapy: A Focus on Prostate Cancer.
Cha HR; Lee JH; Ponnazhagan S
Cancer Res; 2020 Apr; 80(8):1615-1623. PubMed ID: 32066566
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options.
Chakravarty D; Huang L; Kahn M; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4):487-510. PubMed ID: 33008499
[TBL] [Abstract][Full Text] [Related]
14. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
Kim TJ; Koo KC
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in prostate cancer: current state and future perspectives.
Handa S; Hans B; Goel S; Bashorun HO; Dovey Z; Tewari A
Ther Adv Urol; 2020; 12():1756287220951404. PubMed ID: 32952615
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Localized Prostate Cancer: The Next Frontier?
Patel D; McKay R; Parsons JK
Urol Clin North Am; 2020 Nov; 47(4):443-456. PubMed ID: 33008495
[TBL] [Abstract][Full Text] [Related]
17. [Targeted molecular therapy and immunotherapy for prostate cancer].
Grüllich C; Nößner E; Pfister D; Grünwald V
Urologe A; 2020 Jun; 59(6):687-694. PubMed ID: 32303774
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer: MDSCs and immune system in Prostate cancer.
Sanaei MJ; Salimzadeh L; Bagheri N
J Leukoc Biol; 2020 Jan; 107(1):43-56. PubMed ID: 31721301
[TBL] [Abstract][Full Text] [Related]
19. Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer.
Wu W; Wang X; Le W; Lu C; Li H; Zhu Y; Chen X; An W; Xu C; Wu Q; Wang L
Front Immunol; 2022; 13():1001297. PubMed ID: 36700224
[TBL] [Abstract][Full Text] [Related]
20. Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study.
Zhong W; Shen Z; Wu Y; Mao X; Kong J; Wu W
Front Immunol; 2022; 13():1014981. PubMed ID: 36389756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
